Abstract 883P
Background
Mandibular bone resection is indicated in case of bone invasion or close contact with the tumor. The microvascular bone free flap (MBFP) is the reconstruction of choice. Despite a higher risk of complications, it allows oral rehabilitation. However, many patients do not benefit from it. We sought to assess the rate of non-rehabilitated patients and the reasons why.
Methods
This multicenter study was carried out in 6 centers in France. Patients were included if treated between January 2017 and January 2022 for head and neck carcinoma with MBFP. Patients who had relapsed or died were excluded. Included patients completed a telephone questionnaire.
Results
Of the 175 identified patients, 104 patients were finally included. Median follow-up since initial surgery was 26 months (min 18-max 60 months). MBFP consisted of a fibular free flap in 83% of cases, a scapular free flap in 16% of cases and an iliac crest free flap in 1% of cases. 61 patients (59%) had no oral rehabilitation. 17% of these patients had never been informed of the possibilities of oral rehabilitation, and 20% of these patients had never met any oral rehabilitation specialist. 22% of patients had an unsuccessful attempt at oral rehabilitation (removable prosthesis or implant-supported prosthesis). Of the 43 rehabilitated patients, 81% had a removable prosthesis and 19% an implant-supported prosthesis. Neither the number of osteotomies, nor the complexity of the reconstruction, nor the pre- or post-operative history of radiotherapy, nor the use of cutting guides were statistically associated with oral rehabilitation in this series. Only the presence of an oral rehabilitation specialist in the center had a significant influence on the rehabilitation rate (p=0.004), irrespective of the surgeon's specialty.
Conclusions
This is the first multicenter study to evaluate the rate of oral rehabilitation after free bone flap reconstruction for malignancy. Only 41% of patients benefited from rehabilitation. Regardless of the complexity of the reconstruction, the only factor influencing oral rehabilitation was the presence of an oral rehabilitation specialist in the center.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
869P - Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab (D) combined with weekly paclitaxel carboplatin in 1st-line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible to cisplatin
Presenter: Jérome Fayette
Session: Poster session 02
870P - POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients of performance status 2 with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)
Presenter: Martin Forster
Session: Poster session 02
871P - Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study
Presenter: Lara Iglesias Docampo
Session: Poster session 02
873P - Nivolumab (NIVO) in the first-line (1L) or second-line (2L) and later (2L+) settings in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from the German non-interventional study (NIS), HANNA
Presenter: Andreas Dietz
Session: Poster session 02
874P - Preliminary outcomes from a phase Ib/II study of WX390 combined with toripalimab in patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Ye Guo
Session: Poster session 02
875P - A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Dongmei Ji
Session: Poster session 02
876P - Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Xiaozhong Chen
Session: Poster session 02
878P - Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+ oropharyngeal cancer that progressed with prior anti-PD-1 therapy
Presenter: Anthony Kong
Session: Poster session 02